Global Nail Psoriasis Treatment Market, By Treatment (Corticosteroids, Retinoid, Phototherapy, Biologics, Systemic Medications, Others), Diagnosis (Physical Examination, Biopsy, Others), Dosage (Tablet, Injection, Ointment, Others), Route of Administration (Oral, Injectable, Topical, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Industry Trends and Forecast to 2030.
Nail Psoriasis Treatment Market Analysis and Size
According to a systematic review and meta-analysis published in the Journal of the American Academy of Dermatology, the overall prevalence of nail psoriasis in individuals with psoriasis was estimated to be 37.4%. However, the prevalence varied widely depending on the population studied, with a range of 7% to 81%.
Data Bridge Market Research analyses that the nail psoriasis treatment market which was USD 3,461.12 million in 2022, would rocket up to USD 4,736.78 million by 2030, and is expected to undergo a CAGR of 4.0% during the forecast period. This indicates the market value. “Corticosteroids” dominates the treatment segment of the nail psoriasis treatment market owing to the growing demand for better treatment methods. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Nail Psoriasis Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, and Pricing in USD
|
|
Segments Covered
|
Treatment (Corticosteroids, Retinoid, Phototherapy, Biologics, Systemic Medications, Others), Diagnosis (Physical Examination, Biopsy, Others), Dosage (Tablet, Injection, Ointment, Others), Route of Administration (Oral, Injectable, Topical, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Sun Pharmaceutical Industries Ltd. (India), Merck Sharp & Dohme Corp. (U.S.), Dr. Reddy’s Laboratories Ltd. (India), Cipla Inc. (India), AstraZeneca (U.K.), Johnson & Johnson Private Limited (India), Sanofi (France), Novartis AG (Switzerland), Bayer AG (Germany), LEO Pharma A/S (Denmark), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Eli Lilly and Company (U.S.), Sumitomo Dainippon Pharma Co., Ltd. (Japan), Amgen Inc. (U.S.), Zydus Cadila (India), Abbott (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Aurobindo Pharma (India), Lupin (India), and AbbVie Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Psoriasis affecting the nail matrix or nail bed causes nail psoriasis, also known as psoriatic nail dystrophy, which causes specific and non-specific clinical changes in the nail. Psoriatic nail disease is frequently connected with chronic severe cutaneous psoriasis and may be a risk factor for the development of psoriatic arthritis. Nail psoriasis can affect people of various ethnicities, ages, and genders. The appearance of your toenails and fingernails is affected by nail psoriasis. It's possible that they'll thicken, acquire pinprick holes, and alter colour or shape. They can also be tender and painful.
Global Nail Psoriasis Treatment Market Dynamics
Drivers
- Increasing Awareness and Diagnosis
With increasing awareness of nail psoriasis and improved diagnostic techniques, there is a growing number of individuals seeking treatment for this condition.
- Increasing Incidence of Psoriatic Arthritis
Psoriatic arthritis is a common complication of psoriasis, and nail involvement is a common feature of psoriatic arthritis. As a result, there is a growing demand for effective treatments for nail psoriasis in individuals with psoriatic arthritis.
Opportunities
- Development of New Therapies
While there are currently no drugs specifically approved for the treatment of nail psoriasis, there is a significant opportunity for the development of new therapies that target this specific manifestation of psoriasis. This could include the development of new topical or systemic therapies or the repurposing of existing drugs for the treatment of nail psoriasis.
- Collaboration and Partnerships Between Market Players
There is a growing trend towards collaboration and partnerships between pharmaceutical companies, academic institutions, and other stakeholders in the healthcare industry. This approach could be particularly relevant for the development of new therapies for nail psoriasis, as it could bring together expertise from different fields to accelerate the development of effective treatments.
Restraints/Challenges
- Limited Awareness and Under-Diagnosis
Nail psoriasis is often underdiagnosed and can be mistaken for other nail conditions such as fungal infection. Limited awareness among healthcare providers and patients can lead to delays in diagnosis and treatment.
- Lack of specific treatments
There are currently no drugs specifically approved for the treatment of nail psoriasis. While there are several treatment options available for psoriasis in general, these may not be effective for all individuals with nail psoriasis.
This nail psoriasis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the nail psoriasis treatment market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth.
Recent Developments
- In June 2021, Almirall received FDA approval for Klisyri, a topical solution containing tirbanibulin, for the treatment of actinic keratosis, which can also affect the nails
- In September 2020, Leo Pharma received FDA approval for Enstilar, a topical foam containing calcipotriene and betamethasone dipropionate, for the treatment of plaque psoriasis, including nail psoriasis
- In May 2019, AbbVie received FDA approval for Skyrizi, a biologic therapy for the treatment of moderate to severe psoriasis, including nail psoriasis.
Global Nail Psoriasis Treatment Market Scope
The nail psoriasis treatment market is segmented on the basis of treatment, diagnosis, dosage, route of administration, end-users, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Corticosteroids
- Retinoid
- Phototherapy
- Biologics
- TNF-alpha inhibitors
- Adalimumab
- Certolizumab Pegol
- Etanercept
- Etanercept-szzs
- Infliximab
- Interleukin-17 inhibitors
- Brodalumab
- Ixekizumab
- Secukinumab
- Interleukin- 23 inhibitors
- Guselkumab
- TIldrakizumab
- Interleukin 12 and 23 inhibitor
- Systemic Medications
- Acitretin
- Apremilast
- Cyclosporine
- Methotrexate
- Others
Diagnosis
- Biopsy
- Physical Examination
- Others
Dosage
- Tablet
- Injection
- Ointment
- Others
Route of Administration
- Oral
- Topical
- Injectable
- Others
End-Users
- Clinic
- Hospital
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Global Nail Psoriasis Treatment Market Regional Analysis/Insights
The global nail psoriasis treatment market is analysed and market size insights and trends are provided by country, treatment, diagnosis, dosage, route of administration, end-users, and distribution channel as referenced above.
The countries covered in the nail psoriasis treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina, and rest of South America as part of South America.
North America is expected to dominate the nail psoriasis treatment market because of the strong base of healthcare facilities, the strong presence of major players in the market, the extraordinary healthcare infrastructure, and the large pool of people having psoriasis.
Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote healthcare, the rising health awareness among the people and growing demand for advanced medical technology for skin care, the large population pool, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The nail psoriasis treatment market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the nail psoriasis treatment market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the nail psoriasis treatment market.
Competitive Landscape and Nail Psoriasis Treatment Market Share Analysis
The nail psoriasis treatment market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major players operating in the nail psoriasis treatment market are:
- Sun Pharmaceutical Industries Ltd. (India)
- Merck Sharp & Dohme Corp. (U.S.)
- Dr. Reddy’s Laboratories Ltd. (India)
- Cipla Inc. (India)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (India)
- Sanofi (France)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- LEO Pharma A/S (Denmark)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Eli Lilly and Company (U.S.)
- Sumitomo Dainippon Pharma Co., Ltd. (Japan)
- Amgen Inc. (U.S.)
- Zydus Cadila (India)
- Abbott (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Aurobindo Pharma (India)
- Lupin (India)
- AbbVie Inc. (U.S.)
SKU-